Saran Saund - 31 Mar 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role
CHIEF BUSINESS OFFICER
Signature
/s/ Saran Saund
Issuer symbol
OTLC
Transactions as of
31 Mar 2021
Transactions value $
$0
Form type
4
Filing time
16 Jul 2021, 17:35:47 UTC
Next filing
08 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLC Common Stock Conversion of derivative security +16,354,961 16,354,961 31 Mar 2021 Direct F1
transaction OTLC Common Stock Award $0 +102,519 +0.63% $0.000000 16,457,480 08 Jul 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLC Series A Convertible Preferred Stock Conversion of derivative security -16,355 -100% 0 31 Mar 2021 Common Stock 16,354,961 Direct F1, F3
transaction OTLC Stock Options Award $0 +216,279 $0.000000 216,279 08 Jul 2021 Common Stock 216,279 $0.1626 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the "Merger"), shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
F2 Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.
F3 Shares of the Series A Convertible Preferred Stock does not expire.
F4 Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.